Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors

被引:176
|
作者
Wang, Huiyuan [1 ]
Jiang, Yifan [1 ]
Peng, Huige [1 ]
Chen, Yingzhi [1 ]
Zhu, Peizhi [2 ]
Huang, Yongzhuo [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
[2] Yangzhou Univ, Coll Chem & Chem Engn, Yangzhou 225009, Jiangsu, Peoples R China
关键词
MicroRNA; Drug delivery; Non-viral vector; Synthetic vector; Cancer therapy; SMALL INTERFERING RNA; MOLECULAR-WEIGHT POLYETHYLENIMINE; NANOPARTICLE-MEDIATED DELIVERY; GENE DELIVERY; IN-VIVO; TARGETED DELIVERY; SYSTEMIC DELIVERY; CO-DELIVERY; CATIONIC LIPOPLEXES; REPLACEMENT THERAPY;
D O I
10.1016/j.addr.2014.10.031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Because of significant changes in their expression in cancer, miRNAs are believed to be key factors in cancer genetics and to have potential as anticancer drugs. However, the delivery of miRNAs is limited by many barriers, such as low cellular uptake, immunogenicity, renal clearance, degradation by nucleases, elimination by phagocytic immune cells, poor endosomal release, and untoward side effects. Nonviral delivery systems have been developed to overcome these obstacles. In this review, we provide insights into the development of non-viral synthetic miRNA vectors and the promise of miRNA-based anticancer therapies, including therapeutic applications of miRNAs, challenges of vector design to overcome the delivery obstacles, and the development of miRNA delivery systems for cancer therapy. Additionally, we highlight some representative examples that give a glimpse into the current trends into the design and application of efficient synthetic systems for miRNA delivery. Overall, a better understanding of the rational design of miRNA delivery systems will promote their translation into effective clinical treatments. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:142 / 160
页数:19
相关论文
共 50 条
  • [1] Non-viral vectors in cancer gene therapy: principles and progress
    Schatzlein, AG
    [J]. ANTI-CANCER DRUGS, 2001, 12 (04) : 275 - 304
  • [2] Non-viral vectors for cancer therapy
    Kaneda, Y
    Tabata, Y
    [J]. CANCER SCIENCE, 2006, 97 (05) : 348 - 354
  • [3] In vivo gene delivery mediated by non-viral vectors for cancer therapy
    Mohammadinejad, Reza
    Dehshahri, Ali
    Madamsetty, Vijay Sagar
    Zahmatkeshan, Masoumeh
    Tavakol, Shima
    Makvandi, Pooyan
    Khorsandi, Danial
    Pardakhty, Abbas
    Ashrafizadeh, Milad
    Afshar, Elham Ghasemipour
    Zarrabi, Ali
    [J]. JOURNAL OF CONTROLLED RELEASE, 2020, 325 : 249 - 275
  • [4] Whither synthetic non-viral vectors in gene therapy?
    Miller, Andrew D.
    [J]. JOURNAL OF GENE MEDICINE, 2008, 10 (04): : 431 - 431
  • [5] Viral and non-viral vectors for cancer gene therapy
    Cristiano, RJ
    [J]. ANTICANCER RESEARCH, 1998, 18 (5A) : 3241 - 3245
  • [6] Recent progress in non-viral nucleic acids delivery
    Salem, Aliasger K.
    Patil, Siddhesh D.
    Burgess, Diane J.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 427 (01) : 1 - 2
  • [7] Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy
    Lee, Ah Young
    Cho, Myung-Haing
    Kim, Sanghwa
    [J]. EXPERT OPINION ON DRUG DELIVERY, 2019, 16 (07) : 757 - 772
  • [8] Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies
    Caffery, Breanne
    Lee, Jeoung Soo
    Alexander-Bryant, Angela A.
    [J]. NANOMATERIALS, 2019, 9 (01)
  • [9] Recent advance of development of viral and non-viral vectors for gene therapy
    Mizuguchi, Hiroyuki
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2006, 126 (11): : 1011 - 1011
  • [10] Delivery of Biomolecules with Non-Viral Vectors
    Biri, Stephanie
    Stock, Fabrice
    Adib, Abdennaji
    Erbacher, Patrick
    [J]. CELLS AND CULTURE, 2010, 4 : 115 - 119